A detailed history of Eversept Partners, LP transactions in Repligen Corp stock. As of the latest transaction made, Eversept Partners, LP holds 163,593 shares of RGEN stock, worth $20.4 Million. This represents 1.93% of its overall portfolio holdings.

Number of Shares
163,593
Previous 194,291 15.8%
Holding current value
$20.4 Million
Previous $24.5 Million 0.6%
% of portfolio
1.93%
Previous 1.85%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$119.79 - $167.35 $3.68 Million - $5.14 Million
-30,698 Reduced 15.8%
163,593 $24.3 Million
Q2 2024

Aug 14, 2024

BUY
$120.0 - $182.95 $22.3 Million - $34 Million
186,054 Added 2258.76%
194,291 $24.5 Million
Q1 2024

May 15, 2024

SELL
$170.78 - $208.42 $298,352 - $364,109
-1,747 Reduced 17.5%
8,237 $1.51 Million
Q4 2023

Feb 14, 2024

SELL
$114.17 - $185.35 $704,314 - $1.14 Million
-6,169 Reduced 38.19%
9,984 $1.8 Million
Q3 2023

Nov 14, 2023

SELL
$138.78 - $176.51 $6.93 Million - $8.81 Million
-49,914 Reduced 75.55%
16,153 $2.57 Million
Q2 2023

Nov 08, 2023

BUY
$138.42 - $180.31 $8.36 Million - $10.9 Million
60,411 Added 1068.09%
66,067 $9.35 Million
Q2 2023

Aug 14, 2023

BUY
$138.42 - $180.31 $8.36 Million - $10.9 Million
60,411 Added 1068.09%
66,067 $9.35 Million
Q1 2023

Nov 08, 2023

SELL
$154.26 - $198.1 $7.92 Million - $10.2 Million
-51,348 Reduced 90.08%
5,656 $952,000
Q1 2023

May 15, 2023

SELL
$154.26 - $198.1 $7.92 Million - $10.2 Million
-51,348 Reduced 90.08%
5,656 $952,000
Q4 2022

Nov 08, 2023

BUY
$162.42 - $220.56 $8.67 Million - $11.8 Million
53,363 Added 1465.61%
57,004 $9.65 Million
Q4 2022

Feb 14, 2023

BUY
$162.42 - $220.56 $8.67 Million - $11.8 Million
53,363 Added 1465.61%
57,004 $9.65 Million
Q3 2022

Nov 08, 2023

SELL
$160.42 - $256.21 $329,181 - $525,742
-2,052 Reduced 36.04%
3,641 $681,000
Q3 2022

Nov 14, 2022

SELL
$160.42 - $256.21 $329,181 - $525,742
-2,052 Reduced 36.04%
3,641 $681,000
Q2 2022

Nov 08, 2023

SELL
$140.68 - $188.02 $4.34 Million - $5.8 Million
-30,828 Reduced 84.41%
5,693 $924,000
Q2 2022

Aug 15, 2022

SELL
$140.68 - $188.02 $4.34 Million - $5.8 Million
-30,828 Reduced 84.41%
5,693 $925,000
Q1 2022

Nov 08, 2023

SELL
$161.19 - $257.96 $4.76 Million - $7.62 Million
-29,546 Reduced 44.72%
36,521 $6.87 Million
Q1 2022

May 16, 2022

BUY
$161.19 - $257.96 $5.15 Million - $8.24 Million
31,937 Added 696.71%
36,521 $6.87 Million
Q4 2021

Nov 08, 2023

BUY
$247.59 - $304.47 $45,061 - $55,413
182 Added 4.13%
4,584 $1.21 Million
Q4 2021

Feb 14, 2022

BUY
$247.59 - $304.47 $45,061 - $55,413
182 Added 4.13%
4,584 $1.21 Million
Q3 2021

Nov 08, 2023

BUY
$194.77 - $324.21 $138,286 - $230,189
710 Added 19.23%
4,402 $1.27 Million
Q3 2021

Nov 15, 2021

BUY
$194.77 - $324.21 $138,286 - $230,189
710 Added 19.23%
4,402 $1.27 Million
Q2 2021

Nov 08, 2023

BUY
$165.87 - $220.95 $375,529 - $500,230
2,264 Added 158.54%
3,692 $736,000
Q2 2021

Aug 16, 2021

BUY
$165.87 - $220.95 $375,529 - $500,230
2,264 Added 158.54%
3,692 $737,000
Q1 2021

Nov 08, 2023

SELL
$180.37 - $226.26 $11.7 Million - $14.6 Million
-64,639 Reduced 97.84%
1,428 $277,000
Q1 2021

May 13, 2021

BUY
$180.37 - $226.26 $257,568 - $323,099
1,428 New
1,428 $278,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.92B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.